Lipoprotein News and Research

RSS

A lipoprotein is a biochemical assembly that contains both proteins and lipids. The lipids or their derivatives may be covalently or non-covalently bound to the proteins.

New information about biological outcomes and commuting distance

As populations move even further away from urban centers, more people spend longer hours behind the wheel on their way to and from work. While sedentary behavior is known to have adverse effects on cardiovascular and metabolic health, the impact of long commutes by automobile are less understood. A new study has found that greater commuting distances are associated with decreased cardiorespiratory fitness (CRF), increased weight, and other indicators of metabolic risk.

8 May 2012

Flavan-3-ols, SoyLife can improve biomarkers of CVD risk in postmenopausal type 2 diabetic patients

A new, one-year, double-blind controlled clinical study shows that cacao-flavonoids and soy isoflavones can significantly improve biomarkers of CVD risk in postmenopausal women with type 2 diabetes.

5 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

Dark chocolate good for the heart: Study

A new study finds that dark chocolate may lower the risk of heart disease by lowering levels of blood glucose and bad cholesterol while boosting levels of good cholesterol.

25 Apr 2012

Book aims to improve overall cardiovascular health of its readers

Dr. Antonio M. Gotto Jr., dean emeritus and co-chairman of the board of overseers at Weill Cornell Medical College, is the co-author of a new book called The Living Heart in the 21st Century. The book, a new edition in The Living Heart best-selling series, is the essential resource guide for patients about cardiovascular disease prevention and treatment.

25 Apr 2012

Dark chocolate may reduce risk of cardiovascular disease

Chocolate, considered by some to be the "food of the gods," has been part of the human diet for at least 4,000 years; its origin thought to be in the region surrounding the Amazon basin. Introduced to the Western world by Christopher Columbus after his fourth voyage to the New World in 1502, chocolate is now enjoyed worldwide. Researchers estimate that the typical American consumes over 10 pounds of chocolate annually, with those living on the west coast eating the most. Wouldn't it be great if only chocolate were considered healthy?

25 Apr 2012

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive results from its Phase I clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

21 Apr 2012

New findings on out-of-hand nut consumption and health

In a study published in Nutrition Research, researchers looked at the association of out-of-hand nut (OOHN) consumption with nutrient intake, diet quality and the prevalence of risk factors for cardiovascular disease and metabolic syndrome in both children and adults.

16 Apr 2012

KineMed receives NIH RAID grant to advance FX-5A for heart disease

KineMed Inc. today announced its successful award of a Rapid Access to Intervention Development (RAID) peer-reviewed grant by the National Institute of Health to advance an HDL mimetic, designated FX-5A, designed to reverse atherosclerosis and heart disease.

12 Apr 2012

ECG abnormalities associated with increased risk of CHD in older adults

In a study that included elderly men and women without preexisting cardiovascular disease, major and minor electrocardiographic abnormalities were associated with an increased risk of coronary heart disease (CHD) events and improved the prediction of CHD events such as heart attack, beyond traditional cardiovascular risk factors, according to a study in the April 11 issue of JAMA.

12 Apr 2012

Researchers question wisdom of blocking DP1 in patients prone to cardiovascular disease

Niacin, or vitamin B3, is the one approved drug that elevates "good" cholesterol (high density lipoprotein, HDL) while depressing "bad" cholesterol (low density lipoprotein , LDL), and has thereby attracted much attention from patients and physicians. Niacin keeps fat from breaking down, and so obstructs the availability of LDL building blocks.

9 Apr 2012

Removing SR-BI receptor may help protect against breast cancer

Removing a lipoprotein receptor known as SR-BI may help protect against breast cancer, as suggested by new findings presented at the American Association for Cancer Research Annual Meeting 2012 by Jefferson's Kimmel Cancer Center researchers.

4 Apr 2012

Nasal spray to prevent fat and plaque built up in the heart on the horizon

Researchers found a treatment that was much more effective in removing fat from arteries than established methods. The vaccine can be given as an injection or in a slightly different form as a nasal spray. A trial on 144 heart disease sufferers is under way in the US and Canada.

1 Apr 2012

Gene therapy improves chylomicron metabolism in LPLD patients

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today data demonstrating that one-time administration of the gene therapy Glybera (alipogene tiparvovec) is able to markedly improve chylomicron (fat particles in the blood) metabolism following consumption of a low fat meal.

29 Mar 2012

Non-HDL-C levels appear to increase risk of heart attack or stroke in statin-treated patients

Levels of non-high-density lipoprotein cholesterol (non-HDL-C) among statin-treated patients appears to be associated with the risk of developing a major cardiovascular event, such as a heart attack or stroke, as are levels of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B, according to a meta-analysis of data from previously published studies appearing in the March 28 issue of JAMA.

28 Mar 2012

UT Southwestern researcher wins prestigious award from International Atherosclerosis Society

Dr. Helen Hobbs, a preeminent researcher on the genetics of cholesterol metabolism at UT Southwestern Medical Center, has won a prestigious award from the International Atherosclerosis Society.

28 Mar 2012

SAR236553/REGN727 antibody reduces LDL by up to 72% in patients

A novel monoclonal antibody identified in a new study dramatically lowered circulating LDL cholesterol by 40 percent to 72 percent, a development with potential to provide a new option for patients who are resistant to cholesterol-lowering drugs such as statins or to the current standard of care, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012

Lowering LDL at younger age can reduce risk of CHD

Coronary atherosclerosis - a hardening of the arteries due to a build-up of fat and cholesterol - can lead to heart attacks and other forms of coronary heart disease (CHD). Lowering low-density lipoprotein (LDL), or "bad" cholesterol, reduces the risk of CHD, and researchers found that lowering LDL beginning early in life resulted in a three-fold greater reduction in the risk of CHD than treatment with a statin started later in life, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

27 Mar 2012

Positive results from Amgen's AMG 145 Phase 1b study on patients with LDL-C

Amgen announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, by up to 81 percent versus placebo (maximum reduction) in subjects on low to moderate doses of statins/

26 Mar 2012

Obesity in later life linked to decreased mental faculties

The study found said out of 250 test subjects involving people over 59 years old, people between 60 and 70 who had the highest BMIs also had the lowest cognitive function. There was also a connection between visceral fat -- otherwise known as the belly fat around the torso - and poor mental abilities. The study, which was published in the British journal Age and Aging, measured the subjects fat-related measures including BMI, waist circumference and the amount of visceral - which could be close to organs - and subcutaneous -under the skin - fat using a abdominal CT scan. Cognitive ability was determined by a test called a Mini-Mental State Examination.

25 Mar 2012